Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting PH-dependent swelling

• US 5,415,864 A
• Filed: 08/20/1992
• Issued: 05/16/1995
• Est. Priority Date: 04/18/1990
• Status: Expired due to Fees

• Current Assignee: University of Utah Research Foundation (State of Utah)
• Original Assignee: University of Utah Research Foundation (State of Utah)
• Inventors: Kopecek, Jindrich, Kopeckova, Pavla, Kim, Sung W., Brondsted, Helle
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Kulkosky, Peter F.
• Application Number:
  US07/932,914
• Time in Patent Office: 999 Days
• Field of Search: 526/306, 526/307, 424/79, 424/438, 424/78.31, 424/468, 424/487, 424/451, 424/436, 424/78.35
• US Class Current: 424/436
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: C08F 246/00 Copolymers in which the nature of only the monomers in minority is defined

Abstract

Colonic-targeted oral drug dosage forms composed of a drug confined within a crosslinked hydrogel that exhibits pH-dependent swelling and is composed of an ionizable comonomer such as acrylic acid, a nonionizable comonomer such as an acrylamide, and a crosslinking agent that contains an aromatic azobond. Selective drug release in the colon occurs by a combination of pH-dependent swelling of the hydrogel and degradation of the hydrogel by enzymatic cleavage of the azobonds by azoreductases.

Claims

1. A crosslinked hydrogel comprised of:

(a) at least one ethylenically unsaturated comonomer containing no ionizable group;

(b) at least one ethylenically unsaturated comonomer containing an ionizable group; and

(c) a crosslinking agent containing an aromatic azobond,

said copolymer being crosslinked beyond the gel point and containing an amount of (b) such that the hydrogel exhibits pH-dependent swelling wherein the hydrogen imbibes at least about 10% more water at the pH found in the human colon than at the pH found in the human stomach.

2. The hydrogel of claim 1 wherein

(a) is selected from the group consisting of

(i) acrylamides of the formula:

##STR8## where R¹ is hydrogen, methyl or ethyl, and R² and R³ are hydrogen, alkyl of 1 to 8 carbon atoms, hydroxylalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups;

(ii) acrylates of the formula;

##STR9## where R¹ is as defined previously and R⁴ is alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups,

(iii) styrene,

(iv) N-vinylpyrollidone,

(v) acrylonitrile,

(vi) methacrylonitrile,

(vii) N-acryloylmorphine

(viii) vinylacetate, or

(ix) alpha-methylstyrene, and

(b) is selected from the group consisting of

(i) an unsaturated acid of the formula;

##STR10## where R⁵ is hydrogen or alkyl of 1 to 4 carbon atoms, and (ii) N-methylacryloylglycine,

(iii) N-methacryloyl epsilon-aminocaproic acid,

(iv) α

-sulfoethylmethacrylate,

(v) N-methacryloylundecanoic acid,

(vi) maleic anhydride, and

(vii) crotonic acid.

3. The hydrogel of claim 2 wherein the crosslinking agent is of the formula:

##STR11## where R₁ is ##STR12## where x is an integer from 1 to 12 inclusive, and R₆ is H, methyl or ethyl and R₂, R₃, R₄ and R₅ are individually H, CH₃, OCH₃, Br, Cl, F, I, NO₂, CN or C(O)CH₃.

4. The hydrogel of claim 2 wherein the crosslinking agent is 4,4'"'"'-di(methacryloylamino)azobenzene, 4,4'"'"'-di(N-methacryloyl-epsilon-aminocaproyl)aminoazobenzene, or 4,4'"'"'-di(methacryloylamino)-3,3'"'"',5,5'"'"'-tetrachloroazobenzene.

5. The hydrogel of claim 1 wherein (a) constitutes about 10 to about 99 mol % of the hydrogel and (b) constitutes about 1 to about 90 mol % of the hydrogel and the crosslinking agent constitutes about 0.05 to about 15% of the hydrogel.

6. The hydrogel of claim 1 further comprised of (d) a crosslinking agent that does not contain an aromatic azobond.

7. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 1.

8. The oral drug dosage form of claim 7 wherein the drug is dispersed homogeneously in the hydrogel.

9. The oral drug dosage form of claim 7 wherein the hydrogel defines a wall enclosing a lumen and the drug is contained within the lumen.

10. The oral drug dosage form of claim 7 wherein the drug is coated with the hydrogel.

11. The oral dosage form of claim 7 wherein the hydrogel defines the wall of an enclosed capsule or pouch and the drug is contained within the capsule or pouch.

12. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 2.

13. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 3.

14. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 4.

15. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 5.

16. An oral drug dosage form that releases drug selectively in the colon comprising a drug confined within the crosslinked hydrogel copolymer of claim 6.

17. A method of delivering a drug selectively to the colon of a patient comprising:

(a) confining the drug within the crosslinked hydrogel of claim 1; and

(b) administering the thus-confined drug orally to the patient.

22. A process for making the hydrogel of claim 1 comprising the steps of:

forming a solution of (a), (b), and at least one ethylenically unsaturated comonomer having a terminal reactive group;

subjecting the solution to copolymerization conditions whereby a soluble polymeric precursor is formed which contains side chains terminated by said reactive group;

forming a mixture of said precursor and (c) wherein (c) is a bifunctional crosslinking agent; and

subjecting the mixture to crosslinking conditions wherein the crosslinking is carried out beyond the gel point.

23. A process for making the hydrogel of claim 6 comprising the steps of:

forming a solution of (a) and (b), and at least one ethylenically unsaturated comonomer having a terminal reactive group;

subjecting the solution to copolymerization conditions whereby a soluble polymeric precursor is formed which contains side chains terminated by said reactive group;

forming a mixture of said precursor and (c) and (d) wherein (c) and (d) are bifunctional crosslinking agents; and

subjecting the mixture to crosslinking conditions wherein the crosslinking is carried out beyond the gel point.

24. The process of claim 22 wherein

(a) is selected from the group consisting of

(i) acrylamides of the formula:

##STR18## where R¹ is hydrogen, methyl or ethyl, and R² and R³ are hydrogen, alkyl of 1 to 8 carbon atoms, hydroxylalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups;

(ii) acrylates of the formula;

##STR19## where R¹ is as defined previously and R⁴ is alkyl of 1 to carbon atoms, hydroxyalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups,

(iii) styrene,

(iv) N-vinylpyrollidone,

(v) acrylonitrile,

(vi) methacrylonitrile,

(vii) N-acryloylmorphine

(viii) vinylacetate, or

(ix) alpha-methylstyrene, and

(b) is selected from the group consisting of

(i) an unsaturated acid of the formula;

##STR20## where R⁵ is hydrogen or alkyl of 1 to 4 carbon atoms, and (ii) N-methylacryloylglycine,

(iii) N-methacryloyl epsilon-aminocaproic acid,

(iv) α

-sulfoethylmethacrylate,

(v) N-methacryloylundecanoic acid,

(vi) maleic anhydride, and

(vii) crotonic acid.

25. The process of claim 24 wherein the bifunctional crosslinking agent is of the formula:

##STR21## where Y is amino or hydroxy and n is an integer from 1 to inclusive.

26. The hydrogel of claim 1 including an amino-containing drug covalently bound to the copolymer via an aromatic azobond.

27. The copolymer of claim 26 wherein the drug is 5-aminosalicylic acid.

33. The hydrogel of claim 1 wherein the ionizable group is carboxyl.

34. The hydrogel of claim 1 wherein

(a) is selected from the group consisting of N,N-dimethylacryladmie, N-t-butylacrylamide, acrylamide, N-methylacrylamide, N-(2-hydroxypropyl)methacrylamide, and butylacrylate,

(b) is acrylic acid, and

(c) is N,N-di-(methylacryloylamino)azobenzene.

36. The hydrogel of claim 1 wherein the hydrogel includes a third comonomer that has a reactive group prior to crosslinking and the crosslinking agent has prior to crosslinking at least two functional groups that are capable of reacting with the reactive group of the third comonomer.

37. The hydrogel of claim 36 wherein the third comonomer has the formula:

##STR22## where R⁶ is hydrogen, methyl, or ethyl, R⁷ is a residue of a carbonyl activating group, n is 0 or an integer from 1 to 3 inclusive, and X is 1 when n is from 1 to 3 and an integer from 2 to 10 inclusive when n is 0 and the functional groups are amino or hydroxy.

38. The hydrogel of claim 37 wherein

(a) is selected from the group consisting of

(i) acrylamides of the formula:

##STR23## where R¹ is hydrogen, methyl or ethyl, and R² and R³ are hydrogen, alkyl of 1 to 8 carbon atoms, hydroxylalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups;

(ii) acrylates of the formula;

##STR24## where R¹ is as defined previously and R⁴ is alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups,

(iii) styrene,

(iv) N-vinylpyrollidone,

(v) acrylonitrile,

(vi) methacrylonitrile,

(vii) N-acryloylmorphine

(viii) vinylacetate, or

(ix) alpha-methylstyrene, and

(b) is selected from the group consisting of

(i) an unsaturated acid of the formula;

##STR25## where R⁵ is hydrogen or alkyl of 1 to 4 carbon atoms, and (ii) N-methylacryloylglycine,

(iii) N-methacryloyl epsilon-aminocaproic acid,

(iv) 2-sulfoethylmethcrylate,

(v) N-methacryloylundecanoic acid,

(vi) maleic anhydride, and

(vii) crotonic acid.

18. A process for making the hydrogel of claim comprising the steps of:

forming a solution of (a), (b), and (c) wherein (c) contains at least two ethylenically unsaturated bonds in addition to said aromatic azobond; and

subjecting the solution to crosslinking copolymerization conditions wherein the crosslinking copolymerization is carried out beyond the gel point.

19. The process of claim 18 wherein (a) constitutes about 10 to 99 mol % of the total monomers and (b) constitutes about 1 to 90 mol % of the total monomers.

20. The process of claim 18 wherein

(a) is selected from the group consisting of

(i) acrylamides of the formula:

##STR13## where R¹ is hydrogen, methyl or ethyl, and R² and R³ are hydrogen, alkyl of 1 to 8 carbon atoms, hydroxylalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups;

(ii) acrylates of the formula;

##STR14## where R¹ is as defined previously and R⁴ is alkyl of 1 to 12 carbon atoms, hydroxyalkyl of 1 to 12 carbon atoms and 1 to 3 hydroxy groups, or hydroxyalkoxyalkyl of 2 to 12 carbon atoms and 1 to 3 hydroxy groups,

(iii) styrene,

(iv) N-vinylpyrollidone,

(v) acrylonitrile,

(vi) methacrylonitrile,

(vii) N-acryloylmorphine

(viii) vinylacetate, or

(ix) alpha-methylstyrene, and

(b) is selected from the group consisting of

(i) an unsaturated acid of the formula;

##STR15## where R⁵ is hydrogen or alkyl of 1 to 4 carbon atoms, and (ii) N-methylacryloylglycine,

(iii) N-methacryloyl epsilon-aminocaproic acid,

(iv) α

-sulfoethylmethacrylate,

(v) N-methacryloylundecanoic acid,

(vi) maleic anhydride, and

(vii) crotonic acid.

21. The process of claim 20 wherein the crosslinking agent is a compound of the formula:

##STR16## where R₁ is ##STR17## where x is an integer from 1 to 12 inclusive, and R₆ is H, methyl or ethyl and R₂, R₃, R₄ and R₅ are individually H, CH₃, OCH₃, Br, Cl, F, I, NO₂, CN or C(O)CH₃.

35. The hydrogel of claim 18 wherein

(a) is selected from the group consisting of N,N-dimethylacryladmie, N-t-butylacrylamide, acrylamide, N-methylacrylamide, N-(2-hydroxypropyl)methacrylamide, and butylacrylate,

(b) is acrylic acid, and

(c) is N,N-di-(methylacryloylamino)azobenzene.

28. A crosslinked hydrogel copolymer-drug conjugate useful for delivering the drug selectively to the colon comprised of:

(a) at least one ethylenically unsaturated comonomer unit containing no ionizable group;

(b) at least one ethylenically unsaturated comonomer unit containing an ionizable group;

(c) at least one ethylenically unsaturated comonomer unit having a drug covalently bound thereto in an aromatic azobond; and

(d) a bifunctional crosslinking agent, said copolymer being crosslinked at the gel point and containing an amount of (a) such that the copolymer exhibits pH-dependent swelling wherein the hydrogel imbibes at least about 10% more water at the pH found in the human colon than at the pH found in the human stomach.

29. The hydrogel of claim 28 wherein the bifunctional crosslinking agent contains an aromatic azobond.

30. The hydrogel of claim 28 wherein the bifunctional crosslinking agent does not contain an aromatic azobond.

31. The hydrogel of claim 28 wherein the bifunctional crosslinking agent is a mixture of a crosslinking agent containing an aromatic azobond and a crosslinking agent that does not contain an aromatic azobond.

32. A method of delivering a drug selectively to the colon of a patient comprising administering the hydrogel of claim 28 orally to the patient.